Abstract
Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients: (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.).
Highlights
In their prospective multicentre study Stumpf et al report on the humoral and cellular immunity to SARS-CoV-2 vaccination in the so far largest cohort of dialysis patients [1]. mRNA-based COVID-19 vaccines elicit an antibody response in 80-96% of the dialysis population (Table 1), which is substantially higher compared to hepatitis B or influenza vaccinations
More than half of the haemodialysis patients develop a titre below the lowest Anti-SARS-CoV-2 S titre in the control group [2]
Haemodialysis patients with a prior infection mount a substantially higher antibody response [3] comparable to nondialysis individuals [2,4]. In addition to this apparent diminished antibody response in dialysis patients, concerns remain about faster waning of antibody levels after vaccination in this group, as is described after natural infection [5]
Summary
Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.). A Department of Medicine IV, University Hospital, LMU Munich b Institute of Laboratory Medicine, University Hospital, LMU Munich
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
